City Therapeutics, Inc. (CTY)

Price—Loading quote

AI: Overvalued

Price checkCTY closed at $20.43 on October 21, 2026, at 4:00 p.m. EDT, about 13.5% above its $18 IPO price. It is common stock listed on Nasdaq Global Market.

SEC filings identify City Therapeutics, Inc. (CIK 0002143850), common stock, ticker CTY, CUSIP 178782108. The October 19 Form 8-K and final prospectus identify Nasdaq Global Market. The company began trading October 16; this is only four sessions of public trading. The $20.43 quote is a market-close snapshot, not a separately verified execution time. The issuer is the Cambridge RNAi developer, not a similarly named company or a separate preferred/convertible security.

Big pictureAt $20.43, the calculated basic equity value is about $1.09 billion, or roughly $1.23 billion using a simple fully exercised option count, for a Phase 1 company with no approved products.

The final prospectus reports 40,610,057 pre-offering converted common shares and 12,777,777 IPO shares, for a calculated 53,387,834 basic shares. Multiplying by $20.43 gives about $1.091 billion. Adding 6,817,031 outstanding options yields a simple fully exercised 60.2 million shares and $1.230 billion equity value, before option proceeds and treasury-stock adjustments. The company estimated $141.9 million cash at September 30; adding estimated net IPO proceeds of $209.4 million gives an illustrative $351.3 million before actual closing adjustments and subsequent spending. This is not verified enterprise value. The valuation prices in substantial clinical potential.

Business strengthFirst-half 2026 collaboration revenue was $6.36 million, net loss $53.44 million and operating cash use about $43.2 million. Management expects funding into late 2028 after IPO proceeds.

The latest available interim results are unaudited six-month financials through June 30 in the October 16 prospectus; no later quarter was reported. Cash, equivalents and restricted cash totaled $172.1 million at June 30, including about $169.6 million unrestricted. The IPO pro forma June cash figure was hypothetical. Collaboration revenue from Bausch + Lomb and Biogen is not commercial product sales. The company has no approved products. Late-2028 runway is management guidance dependent on spending plans and assumptions.

What could change the storyCITY-FXI, CITY-RBP4 and CITY-TFR2 clinical results are key catalysts; efficacy, safety, spending and dilution remain substantial risks.

Early CITY-FXI Phase 1 cohorts showed dose-related Factor XI knockdown, including approximately 85% three weeks after 150 mg, with initial tolerability described as generally favorable. These are pharmacodynamic/safety observations, not proof of thrombosis prevention or clinical benefit. Management expected more Phase 1 data in late 2026 and a Phase 2 knee-surgery trial in mid-2027; CITY-RBP4 Phase 1 was planned for late 2026. These are forecasts. Bausch + Lomb and Biogen collaborations add external relationships but not guaranteed revenue. Higher cash consumption, trial failure, competition and future equity issuance could undermine the valuation.

AI: News

October 19, 2026: City Therapeutics closes $230 million IPOThe company issued 12,777,777 common shares at $18 each after full exercise of the underwriters' option, for approximately $230 million gross proceeds.

The company confirmed closing of 11,111,111 base shares and 1,666,666 additional shares. Estimated net proceeds were about $209.4 million; this was a prospectus estimate, not an independently reported closing cash balance. The issuer sold the shares to finance CITY-FXI, CITY-RBP4, CITY-TFR2 and platform research. The financing reduces near-term funding pressure but dilutes existing holders and leaves clinical risk unchanged.

October 15, 2026: City Therapeutics prices upsized IPO at $18 per shareCity announced an upsized 11,111,111-share IPO at $18, targeting about $200 million gross proceeds and Nasdaq trading under CTY.

The pricing announcement increased the base deal from the preliminary prospectus and included an option for 1,666,666 additional shares. The offering later closed with that option exercised in full on October 19. Using the final post-IPO basic count of 53.39 million shares, $18 implies approximately $961 million equity value; this is a calculation, not a value announced by the company.

Loading local price history

Revenue

2024

2025

Net income

2024

2025

Free cash flow

2024

2025

Total cash / debt

CashTotal debt

2025

2026

Financial statements

	2025	2024
Revenue	$13.6M	$2.8M
Research & development	$2.0M	$31,000
Operating income	−$59.9M	−$29.1M
Operating margin	−441.84%	−1,047.16%
Net income	−$58.5M	−$27.8M
Net profit margin	−431.39%	−1,002.02%
Diluted EPSper diluted share	-$11.34	-$7.45